Tectonic Therapeutic Q2 EPS $(4.34) Misses $(1.50) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tectonic Therapeutic (NASDAQ:TECX) reported a Q2 EPS loss of $(4.34), significantly missing the analyst consensus estimate of $(1.50) by 189.33%. This represents a 49% improvement over the $(8.51) loss per share from the same period last year.
August 14, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tectonic Therapeutic reported a Q2 EPS loss of $(4.34), missing the analyst estimate of $(1.50) by a wide margin. Despite the miss, the loss is an improvement from the $(8.51) per share loss in the same period last year.
The significant miss on EPS estimates is likely to negatively impact TECX's stock price in the short term. However, the year-over-year improvement in losses may provide some cushion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100